Biomaterial Database

Therapeutic trial of the combination in an eye lotion of adrenaline (0.5 or 1%) and guanethidine (3 or 5%) in cases of open-angle glaucoma. 1979

M Bardy

Treatment of open-angle glaucoma has always been problematical, either because of the lack of efficacy, the inconvenience of multiple medication (handled by the patient with difficulty), or due to the high incidence of side effects. This study showed that an association of adrenaline and guanethidine in drop form, used in cases of open-angle glaucoma, achieved a rapid and lasting stabilisation of intraocular pressure. The main advantage of this form is the combination of two active ingredients for instillation twice daily. In addition, the pH and the nature and concentration of the ingredients are such that side effects, if they occur, do so at the beginning of treatment and are of short duration.

UI	MeSH Term	Description	Entries
D007429	Intraocular Pressure	The pressure of the fluids in the eye.	Ocular Tension,Intraocular Pressures,Ocular Tensions,Pressure, Intraocular,Pressures, Intraocular,Tension, Ocular,Tensions, Ocular
D008297	Male		Males
D009883	Ophthalmic Solutions	Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS.	Eye Drop,Eyedrop,Eyedrops,Ophthalmic Solution,Eye Drops,Drop, Eye,Drops, Eye,Solution, Ophthalmic,Solutions, Ophthalmic
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D004338	Drug Combinations	Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.	Drug Combination,Combination, Drug,Combinations, Drug
D004341	Drug Evaluation	Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.	Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004837	Epinephrine	The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes systemic VASOCONSTRICTION and gastrointestinal relaxation, stimulates the HEART, and dilates BRONCHI and cerebral vessels. It is used in ASTHMA and CARDIAC FAILURE and to delay absorption of local ANESTHETICS.	Adrenaline,4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol,Adrenaline Acid Tartrate,Adrenaline Bitartrate,Adrenaline Hydrochloride,Epifrin,Epinephrine Acetate,Epinephrine Bitartrate,Epinephrine Hydrochloride,Epinephrine Hydrogen Tartrate,Epitrate,Lyophrin,Medihaler-Epi,Acetate, Epinephrine
D005260	Female		Females
D005901	Glaucoma	An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)	Glaucomas
D006145	Guanethidine	An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.	((2-Hexahydro-1(2H)-azocinyl)ethyl)guanidine,Guanethidine Monosulfate,Guanethidine Sulfate,Guanethidine Sulfate (1:1),Guanethidine Sulfate (1:2),Guanethidine Sulfate (2:1),Guanethidine Sulfate (2:1), 14C-Labeled,Ismelin,Isobarin,Octadine,Oktadin,Monosulfate, Guanethidine,Sulfate, Guanethidine

Related Publications

M Bardy

Evaluation of a 5% guanethidine and 0.5% adrenaline mixture (Ganda 5.05) and of a 3% guanethidine and 0.5% adrenaline mixture (Ganda 3.05) in the treatment of open-angle glaucoma.

January 1979, The British journal of ophthalmology,

M Bardy

The combination of guanethidine 3% and adrenaline 0.5% in 1 eyedrop (GA) in glaucoma treatment.

January 1979, The British journal of ophthalmology,

M Bardy

Use of guanethidine 5% and adrenaline 1% in the treatment of severe open angle glaucoma.

April 1977, Transactions of the ophthalmological societies of the United Kingdom,

M Bardy

Timolol and guanethidine plus adrenaline in combination in the treatment of chronic open angle glaucoma.

January 1985, Transactions of the ophthalmological societies of the United Kingdom,

M Bardy

Maintenance therapy of glaucoma patients with guanethidine (3%) and adrenaline (0.5%) once daily.

January 1980, Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. Albrecht von Graefe's archive for clinical and experimental ophthalmology,

M Bardy

A double-blind short-term trial of guanethidine 3% and adrenaline 0.5% combined in one eye drop.

July 1977, Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. Albrecht von Graefe's archive for clinical and experimental ophthalmology,

M Bardy

[Treatment of glaucoma chronicum simplex with a combination of 0.5 percent timolol with 0.5 percent adrenaline plus 0.3 percent guanethidine].

March 1989, Klinische Monatsblatter fur Augenheilkunde,

M Bardy

Guanethidine and adrenaline used in combination in chronic simple glaucoma.

July 1973, The British journal of ophthalmology,

M Bardy

The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.

December 2013, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics,

M Bardy

The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.

January 2009, Journal of glaucoma,